Background Over-the-counter (OTC) medicines are available without prescription, allowing convenience and facilitating self-care. As more OTC drugs become available, concerns regarding misuse have increased. This study explored pharmacists' perceptions about OTC drugs misuse, products involved and measures taken to address misuse.
Introduction
An increasing range of drugs is available for the public to buy without a prescription. These drugs are commonly known as over-the-counter (OTC) drugs or non-prescription medicines (NPMs). The rationale for this increase is to promote selfcare, increase convenient and safe access to medicines and reduce the demand on medical services. In 2012, the OTC medicines industry was worth £2.3 billion in the UK, with pain relief and cough or cold remedies being the most commonly sold categories of product. 1 If every customer who bought an OTC product in 2012 had instead gone to their doctor, NHS expenditure would have increased by £30 billion to fund consulting time alone. 2 OTCs or NPMs include medicines in the UK legal categories 'general sales medicines' (GSL; sold from any retail outlet) and Pharmacy only (P; sold only from a pharmacy, under the supervision of a pharmacist). There is a rigorous process managed by the Medicines and Healthcare Products Regulatory Agency (MHRA) whereby medicines are categorized depending on evidence of safety. Despite this, as the range of OTC medicines has increased, so have concerns about misuse, abuse and dependence.
'Misuse' of a medicine is defined as using an inappropriate quantity of a drug or use for an extended duration, beyond recommended guidelines (N. Fingleton, personal communication). 3 Examples of OTC misuse include taking higher than recommended doses of analgesics such as paracetamol, ibuprofen or codeine or of excessive doses of laxatives. 'Abuse' of a medicine is to take it for an effect other than the licensed medical one, e.g. to achieve a 'high' (N. Fingleton, personal communication). 3 Drugs likely to be abused include codeine that can be taken for its psychoactive effects, and pseudoephedrine, a decongestant that can be used in the illegal manufacture of methamphetamine or 'crystal meth', a highly addictive illegal stimulant. 4 Dependence is the compulsion to repeatedly use a medicine and a difficulty stopping its use voluntarily (N. Fingleton, personal communication).
3 From a public health perspective, drug misuse, abuse and dependence are associated with a range of health risks such as overdose and ultimately increased demand on scarce health resources. 5 Records are not routinely kept of the supply of OTCs; therefore, misuse and abuse are difficult to quantify. A recent systematic review concluded that 'OTC medicine abuse is a recognized problem internationally but is currently incompletely understood'. 6 Since then studies have tried to quantify misuse, abuse and dependence in both pharmacy customers and the population. A French study used targeted surveys of pharmacy customers requesting specific products with misuse/abuse potential, specifically codeine combinations with paracetamol and H1 antihistamines. Misuse and dependence of codeine/paracetamol products were evident in 6.8 and 17.8% of customers, respectively. 7 This high prevalence of dependence compared with a previous French study 8 using the same methodology was considered due to the inclusion of psychological criteria for assessing dependence. In comparison, prevalence in the general population in the UK has been determined and a lifetime prevalence of abuse of 4.1% 4 has been reported. For misuse, the lifetime prevalence for using a higher dose than recommended was 11.9%, 10.6% for using more often than recommended and 10.6% for using for a longer time than recommended. 4 Another smaller UK survey found that around a third of people under the age of 60 had personally encountered abuse of OTC medicines. 9 As part of a programme of work on the management of drug misusers, the authors have undertaken community pharmacy surveys in 1995, 2000, 2006 and most recently in 2014. 10 These surveys tracked changes in the involvement of community pharmacies in management of drug misusers and included sections on perceptions and management of OTC misuse in the local pharmacy areas. Published comparison of the 1995 and 2000 data found that diphenhydramine (in the specific form of Nytol), an antihistamine-based sleep aid, was the most cited as suspected of misuse and kaolin and morphine and codeine linctus had become less commonly named as OTC drugs of misuse, although still remained a concern. 11 This shift in demand may reflect changing cultures around drugs and their marketing, with the more old-fashioned remedies becoming less frequently stocked by pharmacists or less frequently sought by customers.
The aim of this paper is to report the findings of the 2014 survey with respect to the perceptions pharmacists have of misuse of OTC medicines in their pharmacy, the products that are most commonly suspected of misuse, if and how perceived OTC misuse affects sales policies and how this is managed. It will also compare these findings to those in the previous three surveys to determine what changes have taken place over time. For simplicity, the authors have chosen to use the term of 'misuse' in the survey and remainder of this paper as the umbrella term for all three categories of inappropriate use.
Methods
The study design, as in earlier years, was a cross-sectional postal survey. The population was all registered community pharmacists in Scotland (n ¼ 1246).
The questionnaire included a total of 65 questions relating to the wider programme of work on providing services to drug misusers, and attitudes to drug misusers (reported elsewhere), 10 demographics ( pharmacist age, gender, location, Health board area and type of pharmacy) together with four questions on the misuse of OTC drugs. These determined perceptions of whether or not OTC drugs were being misused, the names of the drugs likely to be misused, whether or not sales policies for these products had changed as a result of perceptions of misuse and if so what these changes had been. Questions relating to OTC were identical to those used in previous surveys. The term 'misused' was used rather than 'abused' as it was considered to be the broadest term. The questionnaire was previously validated. 12 The questionnaire packs were posted in spring 2014 addressed to 'The Pharmacist in Charge'. The packs also included an invitation letter, a reply-paid envelope and an identifiable postcard that pharmacists were asked to return separately, but at the same time as the completed questionnaires. This allowed identification of non-respondents while maintaining anonymity of the individual responses. Reminders were sent after 3 weeks, and after a further 2 weeks, nonresponders were contacted by telephone to remind them to return the questionnaire.
All 2014 data were entered into an SPSS database, with double data entry performed on a random 10% of questionnaires as a quality assurance measure. The error rate was 0.01%. Free-text answers were thematically coded. Data from all surveys were imported to a separate database, with care taken to ensure exact mapping of questions across the four cohorts. Analyses included descriptive frequencies of the demographics and OTC-related data, with longitudinal trends identified using x 2 tests for categorical variables.
Results
The 2014 survey response rate was 57% (709/1246). Pharmacies belonging to national multiples were less likely to respond than those in small chains or single outlets (58% compared with 66%; P ¼ 0.003 x 2 8.904, df 1). Just over 80% (n ¼ 573) of responders in 2014 believed OTC misuse occurred in their local geographical area and there was a significant increase in this belief across all years (P , 0.001, x 2 test for trend 54.027, df 9) (see Table 1 ). Across Health Board regions, this perception ranged from 55.6% for respondents in the Islands (Orkney, Shetland and Western Isles combined) compared with 88.6% in Lanarkshire (See Fig. 1 ). Urban pharmacies were more likely to perceive misuse, with 83.9% saying drugs were misused in their area, compared with 74.1% in rural pharmacies (P , 0.001, x 2 891.579, df 16). The types of products suspected of being misused are shown in Table 2 . In 2014, co-codamol was the commonest single drug, having featured in 48.5% of responses. Indeed, overall, the products most frequently mentioned were codeine-containing products (Nurofen Plus, co-codamol, Solpadeine and other codeine products) which were noted in 95.8% of responses, often multiple times under different product names. This compared with diphenhydramine (specifically Nytol) has been the most frequently mentioned product in all previous surveys. Trends in the use of different products are shown graphically in Fig. 2 . Table 1 Perception of OTC misuse and effect on sales policies Another change in the product types perceived as being misused was the decrease in reports of laxative misuse. In 1995, 12.3% of pharmacists had cited laxatives as being misused but in 2014 just 2.6% did. Also notable is the fact that none of the top 10 products reported in 2014 were stimulants. Of the products in Table 2 , three contained stimulants; Actifed, Do-Do tablets and Chesteeze (all containing pseudoephedrine or ephedrine) and were reported as misused by 21, 6 and 2 respondents, respectively. These had all been much more common concerns in previous surveys, with Do-Do tablets alone being mentioned in 60 responses in 2005.
There was also a large number of 'other' responses, often mentioned only once or twice each. These included 'vitamin C', 'eye drops' and 'Motilium' (domperidone).
Of the 573 pharmacists in the most recent survey who believed that OTC products were misused 'in their local area', the majority (91.3%, 524) said that this did effect their sales policy (Table 1) , but there was no significant difference across years (P ¼ 0.05, x 2 7.819, df 3). In 2014, the most frequent reasons noted on how sales policy was affected were refusing sales, questioning the patients and offering advice/pharmacist involvement. Other ways in which sales policies were affected in all four surveys are shown in Table 3 .
Forty-six respondents reporting suspected OTC misuse in their area in 2014 said they had not changed their sales policies to reflect the suspected misuse. However, when the free-text responses were coded, 31 of those respondents had adopted some sort of strategy such as 'I refuse sale if or when I notice' or 'each visit is an opportunity for an intervention' ( Table 2) . Of the remaining 15 responses, 10 felt that the current legal restrictions and guidance were sufficient, and 5 cited finances, company pressure not to restrict sales and feeling it was futile as people would simply go elsewhere. Contains codeine.
*In the 1995 survey, Nurofen not Nurofen Plus was noted by respondents. **Codeine containing products includes 18 entries of codeine which cannot be bought as an OTC drug. ***Includes one of just 'morphine' which cannot be bought over-the-counter on its own.
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Discussion
Main finding of this study
Since 1995, there has been an increase in the number of pharmacists who perceived OTC products were being misused in their area, with most change in the period from 2006 to 2014. There has also been a steady change in the nature of the products suspected of misuse with a switch from diphenhydramine (Nytol) in earlier years to codeine-containing products in 2014. 
Table 3 Sales policy
How is sales policy affected in the pharmacy? 
What is already known on this topic
Previous studies of pharmacists' perspectives found that sleep aids were perceived to be the most misused OTC products, although codeine-containing products were noted as suspected of misuse. 11 Research on prevalence from the public and patient perspective also identified codeinecontaining products and antihistamine sleep aids as those most associated with misuse and dependence. Research in the general population found that the lifetime prevalence of dependence was 2%.
4 Codeine-containing analgesics were the most frequently mentioned (n ¼ 4), but analgesics without codeine, a herbal sleep aid and smoking cessation products were also mentioned. 4 A systematic review of OTC medicine abuse found that codeine-containing products were frequently the drugs of dependence. 6 A further study exploring OTC addiction and reasons also found codeine-containing analgesics were the primary medicines being abused. 13 Studies exploring reasons for misuse and dependence identified self-management of chronic conditions such as pain 13 and headache 7 as causes. Cooper's 2011 review concluded that greater awareness of the addiction potential of OTC medicines is needed for the public, pharmacists and medical prescribers. 6 
What this study adds
This study allowed the changes over time to be documented and found that there has been a large increase in the number of pharmacists who perceive OTC misuse in their area indicating their awareness was high. There have also been changes to the types of drugs perceived to be misused. Codeine-containing products are now the commonest cited drugs mentioned in 95.8% of responses. This concurs with the findings from the public and those who are dependent on OTC products. 4,13 Co-codamol specifically was the commonest codeine-containing product noted in 2014 and featured in 48.5% of responses, having superseded Nurofen Plus as the highest ranking codeine product. This may be because co-codamol is significantly cheaper than Nurofen Plus. While most codeine-containing products had increased in use, Syndol did not follow the same pattern, reflecting recent licensing negotiations and resultant shortages. 14 Similarly Kaolin and Morphine, Feminax (codeinecontaining analgesic) and Codeine Linctus had a trend of reducing use. This may reflect changes in their clinical indication as Kaolin and Morphine are no longer recommended for acute diarrhoea, and Codeine Linctus is not recommended for cough due to the side effect of constipation. 15 Both latter products were generally not displayed or no longer stocked. It may well be that awareness of their propensity for misuse caused a decrease in pharmacies willing to stock or supply them.
Other studies on OTC misuse, particularly in the USA, have found dextromethorphan to be a commonly misused substance. 16 However, this was not particularly reflected in the results of this survey. The only two dextromethorphan products seen in the responses were Benylin (a brand of cough medicine and Night Nurse (which also contains paracetamol and a sedating antihistamine) and they had been cited just 24 and 14 times, respectively. This may reflect a cultural difference in Scotland compared with that in USA. However, it is notable that both of these products had been more commonly reported in the 2000 survey (71 and 44 responses, respectively), perhaps reflecting a time trend rather than just a cultural difference. In France, both codeine-containing products and sedative H1 antihistamine products were also noted as products of misuse and dependence. 7 Across all years, sales policies had been influenced by misuse of OTC drugs, although reported change had slightly decreased in 2014 compared with other years. Pharmacies were taking measures to reduce the opportunities for misuse, with the commonest types of action taken being refusal of sales, ensuring pharmacist involvement in sales and giving counselling including referring patients to their GPs. These actions would appear to be appropriate and responsible measures to take in minimizing OTC misuse. The development of electronic summary care records and recent announcements that community pharmacy in England will be given access to these may ultimately be a way for better communication between health professionals regarding suspected misuse. However, at the moment, other than GPs, all other healthcare professionals only have read access to these records. Given that previous research has highlighted that those with dependence often start misusing products in an attempt to manage chronic health problems such as pain, 7, 13 this might be a way of identifying misuse before if develops into dependence.
Interestingly, the types of changes made to individual pharmacy policy regarding sales requests changed over the course of the four surveys. For example, hiding or storing products out of sight had been a popular decision in the previous three surveys but was now much further down the list, suggesting that responses may now be more nuanced or considerate of getting help for those affected. A similar pattern is seen for simply not stocking the offending products. It is also notable that, despite many pharmacists referring customers to their GP, none mentioned having referred people directly to specialist addiction services. This could suggest that the pharmacists do not want to presuppose addiction despite evidence of misuse or that GPs are an accessible first port of call.
Limitations of this study
The response rate to the postal questionnaire in 2014, at 56.9%, was lower than previous years reflecting the general trend of reducing survey responses. It, therefore, may be less generalizable than earlier surveys, and this may confound the observed trends in responses. A strength is the repeated use of a questionnaire over four cohorts allowing trends in misuse to be quantified.
In common with all surveys, responses are perceptions only and not objective assessments. Pharmacists may now be more alert and aware of misuse than before, and this could be the cause of increased reporting. In England, recently the Centre for Pharmacy Postgraduate Education guidelines highlight codeine-containing medicines as a particular issue and suggests refusing large sales, referring customers and placing products out of sight; all of which were featured in the responses from pharmacists. 17 This population of Scottish pharmacists will not have had direct access to this material but other training events may have raised awareness. As a result, there may be increased vigilance. Further research could compare the findings to that being observed in practice by GPs and drug treatment services.
Conclusion
In conclusion, pharmacists' perception of misuse of OTC medicines taking place in their area, have increased significantly since 2006, before which the figures had remained near constant since 1995. The products being misused have changed with codeine-containing products now the most commonly mentioned. Pharmacists have adapted their sales policies to combat perceived misuse and in general are taking appropriate measures. In future, pharmacists should be given guidance on the best ways to reduce OTC misuse to ensure more uniformity. Care pathways for those with suspected OTC dependence should be defined.
